Last Updated : December 12, 2022
Details
FilesGeneric Name:
atezolizumab
Project Status:
Complete
Therapeutic Area:
Small Cell Lung Cancer
Manufacturer:
Hoffmann-La Roche Limited
Call for patient/clinician input open:
Brand Name:
Tecentriq
Project Line:
Reimbursement Review
Project Number:
PC0277-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Tecentriq for the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance Tecentriq should be continued until loss of clinical benefit or unacceptable toxicity.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Tecentriq in combination with carboplatin and etoposide is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient/clinician input open | December 17, 2021 |
| Call for patient/clinician input closed | February 18, 2022 |
| Submission received | January 24, 2022 |
| Submission accepted | February 07, 2022 |
| Review initiated | February 08, 2022 |
| Draft CADTH review report(s) provided to sponsor for comment | April 29, 2022 |
| Deadline for sponsors comments | May 10, 2022 |
| CADTH review report(s) and responses to comments provided to sponsor | June 30, 2022 |
| Expert committee meeting (initial) | July 13, 2022 |
| Draft recommendation issued to sponsor | July 25, 2022 |
| Draft recommendation posted for stakeholder feedback | August 04, 2022 |
| End of feedback period | August 18, 2022 |
| Final recommendation issued to sponsor and drug plans | September 01, 2022 |
| Final recommendation posted | September 20, 2022 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | September 16, 2022 |
| CADTH review report(s) posted | December 8, 2022 |
Files
Last Updated : December 12, 2022